Target Price | $305.77 |
Price | $250.98 |
Potential |
21.83%
register free of charge
|
Number of Estimates | 26 |
26 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2025 .
The average Alnylam Pharmaceuticals, Inc target price is $305.77.
This is
21.83%
register free of charge
$400.00
59.38%
register free of charge
$178.00
29.08%
register free of charge
|
|
A rating was issued by 33 analysts: 23 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 8 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2025 of
21.83%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion $ | 1.83 | 2.23 |
76.23% | 22.06% | |
EBITDA Margin | -12.48% | 1.22% |
82.52% | 109.78% | |
Net Margin | -24.81% | -11.39% |
78.52% | 54.08% |
27 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2024 . The average Alnylam Pharmaceuticals, Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2024. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2024. The average Alnylam Pharmaceuticals, Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.52 | -1.97 |
62.15% | 44.03% | |
P/E | negative | |
EV/Sales | 14.48 |
25 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Alnylam Pharmaceuticals, Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Alnylam Pharmaceuticals, Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.